AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01415128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Once a day dosing of Omeprazole (40 mg) for 8 days
Study NCT01415128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Single dose of Rosiglitazone (8 mg) for 1 day
Study NCT01415128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desipramine
Description: Single dose of Desipramine (50 mg) for 1 day
Study NCT03410459 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: DEXA (= Dual-energy x-ray absorptiometry)
Description: measurement of vertebral bone and hip bone mineral density
Study NCT02064920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for donepezil hydrochloride capsule
Study NCT02064920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for donepezil hydrochloride capsule
Study NCT02064920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5 mg donepezil hydrochloride capsule.
Study NCT02064920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg donepezil hydrochloride capsule.
Study NCT01614938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 initial dose before radiation, then 250 mg/m2 weekly during radiation
Study NCT01614938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3
Study NCT01614938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1
Study NCT01614938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1
Study NCT01614938 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: a total dose of 66-70.4Gy in 30-32 fractions over 6-6.5 weeks planned to be delivered to the PTV of gross tumor
Study NCT01614938 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: a total dose of 66-70.4Gy in 30-32 fractions over 6-6.5 weeks planned to be delivered to the PTV of gross tumor
Study NCT01614938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3, then 6 cycles of concomitant chemotherapy every week with cisplatin 30 mg/m2 D1
Study NCT00290186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Treatment
Description: 100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
Study NCT00290186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Air Treatment
Description: 14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
Study NCT01841463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1446A-05
Description: - In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) \& vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The max tolerated dose (MTD) of P1446A-05 \& vemurafenib co-administered will be determined. In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, \& 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration. Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples \& undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
Study NCT01841463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib (Zelboraf®)
Description: * In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.~* In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, and 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle~* Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples and undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
Study NCT04354220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: capnography monitoring
Description: routinely used capnography monitoring
Study NCT04354220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: arterial blood gas
Description: Routinely taken arterial blood gas values
Study NCT03388918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Blood pressure (A\&D Medical UA 767PBT), weight (A\&D Medical UC-321PBT), step counters(Fitbit Zip \& Charge), sleep sensor (Beddit 3), tablet (iPAD Air 2) \& transmitter (Qualcomm Life, QWH-HUB-V1.0E)
Study NCT04801875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected Exercise
Description: The violin and ney groups performed a structured exercise training program 3 times a week for a total of 8 weeks. Adherence to the exercise training program was checked using a follow-up schedule to ensure regular participation of the musicians. The 8-week exercise training program was given with same physiotherapist under the same conditions. The every exercise session consisted of warm-up (3-5 min), main exercise (30-35 min) and cooling periods (3-5 min). The main exercise period was included ROM (10 min), stretching (5-7 min), isometric (5-10 min) and stabilization exercises (5 min).
Study NCT01591525 — intervention group
Intervention type: BEHAVIORAL
Intervention: Education on risk factors for Type II Diabetes
Description: one-on-one education provided by a nurse practitioner or physician
Study NCT01739569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary treatment
Description: Dietary treatment with healthy lunch and snack meal during working hours
Study NCT02632565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT02632565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study NCT02878551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation program
Description: multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
Study NCT01777412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT02237781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropins
Description: The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .
Study NCT01879787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS involves application of very low-amplitude direct currents(2 mA or less) via surface scalp electrodes.This produces a sub-sensory level of electrical stimulation which remains imperceptible by most people during its application. In a small percentage of patients it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease corticomotor excitability. Cathodal tDCS decrease and anodal tDCS increase the motor cortex excitability.
Study NCT01879787 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS involves application of very low-amplitude direct currents(2 mA or less) via surface scalp electrodes.This produces a sub-sensory level of electrical stimulation which remains imperceptible by most people during its application. In a small percentage of patients it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease corticomotor excitability. Cathodal tDCS decrease and anodal tDCS increase the motor cortex excitability.
Study NCT00890253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab (Simulect)
Description: 20 mg basiliximab (Simulect) iv on day 0 and 4 after OLT
Study NCT00890253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: 1080 mg q12 EC-MPS (Myfortic) po starting within 24h after OLT
Study NCT00890253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 1 mg q12 everolimus (Certican) po starting on 10th post-operative day
Study NCT00890253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
Study NCT04173715 — intervention group
Intervention type: BEHAVIORAL
Intervention: Older Adults Group.
Description: Physical activity and energy expenditure quantification
Study NCT04173715 — intervention group
Intervention type: BEHAVIORAL
Intervention: Low Physical Function Status Group
Description: Physical activity and energy expenditure quantification
Study NCT04173715 — intervention group
Intervention type: BEHAVIORAL
Intervention: Medium Physical Function Status Group
Description: Physical activity and energy expenditure quantification
Study NCT04173715 — intervention group
Intervention type: BEHAVIORAL
Intervention: High Physical Function Status Group
Description: Physical activity and energy expenditure quantification
Study NCT04202523 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Liver cancer radiofrequency ablation is a clinical treatment method that uses electrode needles to penetrate the skin and liver into the tumor and completely destroy the tumor through the principle of heat production to achieve the purpose of treating tumors.
Study NCT04202523 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Liver cancer radiofrequency ablation is a clinical treatment method that uses electrode needles to penetrate the skin and liver into the tumor and completely destroy the tumor through the principle of heat production to achieve the purpose of treating tumors.
Study NCT04202523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMRT & SBRT
Description: Tumor radiation therapy is a local treatment method using radiation to treat tumors. Radiation includes alpha, beta, and gamma rays produced by radioactive isotopes and x-rays, electron beams, proton beams, and other particle beams produced by various types of x-ray therapy machines or accelerators. Current mainstream radiotherapy technologies include stereotactic radiation therapy (SRT). Stereotactic radiation therapy (SRT) includes three-dimensional conformal radiation therapy (3DCRT) and three-dimensional conformal intensity modulated radiation therapy (IMRT).
Study NCT02964299 — intervention group
Intervention type: DEVICE
Intervention: Mandibular advancement bite block
Description: Mandibular advancement bite block that provides mandibular advancement by 3 mm, 6 mm, or 9 mm from neutral position
Study NCT01255969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Personalized exercise program
Study NCT01387165 — intervention group
Intervention type: DRUG
Intervention: Treatment
Description: were receiving an oral hypoglycemic agent (OHA) or insulin
Study NCT00418665 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMG 531
Description: AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.
Study NCT00418665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the control group will receive placebo via subcutaneous injection.
Study NCT00918047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-804O
Description: Open Label study
Study NCT01293968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen, Diphenhydramine and Aluminium MgS
Description: 3 times daily for 3 days
Study NCT01293968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine and Aluminium MgS
Description: 3 times daily for 3 days
Study NCT02603471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational group
Description: A pamphlet will be provided to the participants with information about ART adherence, HIV and relapse prevention.
Study NCT02603471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging CBT (TXT-CBT)
Description: Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
Study NCT04224844 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: The block will be performed before the surgery. The spinous process of T2 or T3 wil be identified by an ultrasound guide, with the probe positioned longitudinally. A block needle will be inserted in the caudo-cephal direction. After the injection site is confirmed by 3 ml of physiological solution and correct position of the needle tip is confirmed, bupivacaine will be injected. The patients assigned to this group will also receive an intravenous patient-controlled analgesia device containing tramadol postoperatively.
Study NCT04224844 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Control group will receive only patient-controlled analgesia device containing tramadol. No block will be performed.
Study NCT04084106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin
Description: Oral administration
Study NCT04084106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Oral administration
Study NCT04084106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanic acid
Description: Oral administration
Study NCT04952740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPC+PCI
Description: Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.) + immediate post-ischemic adaptation: 30 seconds balloon inflation and 30 seconds deflation for 3 cycles
Study NCT04952740 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No IPC
Description: Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.
Study NCT00853749 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13-valent pneumococcal conjugate vaccine (13vPnC)
Description: 0.5 mL intramuscular injection
Study NCT00853749 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Collection of 10 mL of blood
Study NCT00744133 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NF54 P. falciparum isolate
Description: 1, 3, 5 or N bites from aseptically-raised Anopheles stephensi female mosquitoes infected with Plasmodium falciparum parasites of the NF54 strain.
Study NCT01188720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: 30 minutes of moderate to intense physical activity including strength training and cardiovascular activity.
Study NCT01188720 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: 30 minutes of moderate to intense physical activity including strength training and cardiovascular activity.
Study NCT00591214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424 (Telaprevir)
Description: Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg)
Study NCT00495820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.
Study NCT00495820 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard inactive pill.
Study NCT00161460 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: colorectal cancer screening intervention
Description: Enrolled subjects receive tailored education from a registered nurse who also facilitates ordering and completion of screening tests
Study NCT03653130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crossroads Orchestra Participatory Music Program
Description: The intervention is a participatory music program where adults engage in music-making as members of a strings orchestra.
Study NCT04169022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sample collection
Description: Sample collection blood and/or bone marrow
Study NCT03337542 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AR101
Description: AR101
Study NCT00282178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: 25-50 mg once daily
Study NCT00282178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study NCT00282178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: 16-32 mg once daily 12 weeks
Study NCT03021395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine at a dose of 20mg/㎡/d on day 1-5.
Study NCT03352700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3L PEG
Description: Group A patients (n = 300) used only 3L PEG before colonoscopy.
Study NCT03352700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3L PEG+Dyclonine Hydrochloride Mucilage
Description: Patients in group B (n = 300) were additionally advised to Dyclonine Hydrochloride Mucilage plus 3 L PEG
Study NCT02726971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoston
Description: Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
Study NCT02726971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoston
Description: Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
Study NCT00199914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shortwave diathermy
Description: continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
Study NCT00199914 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Shortwave diathermy
Description: continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
Study NCT02786134 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan
Description: A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.
Study NCT02786134 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.
Study NCT05075395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARO therapy seal
Description: PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
Study NCT02765087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical History
Description: Oriented Survey and complete physical exam.
Study NCT02765087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical History
Description: Oriented Survey and complete physical exam.
Study NCT02765087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Nose
Description: Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA
Study NCT02765087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Nose
Description: Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA
Study NCT02765087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest CT
Study NCT02765087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest CT